Diagnostics and healthcare platform Orange Health is raising$30 millionin fresh funding, with the impact of the capital infusion likely to reflect in its FY27 annual results. During FY26, the company’s revenue grew 65% year-on-year while losses widened to nearly Rs 100 crore as it expanded across tier I cities. According to its financial statements filed with the Registrar of Companies (RoC), the Bengaluru-based startup’s revenue from operations surged to Rs 138.6 crore in the fiscal year ended March 2026 from Rs 84 crore in FY25. Founded in 2020 by Dhruv Gupta and Tarun Bhambra, Orange Health Labs is a full-stack diagnostics platform offering on-demand testing and at-home sample collection for routine diagnostics. Beyond D2C services, Orange Health has onboarded over 2,000 clinics on its platform to enable faster diagnosis and clinical decision-making. The company claims to have added over 60 company-owned collection centres in the past year, with nearly 50 of them located in Bengaluru. Diagnostics services remained the sole source of Orange Health’s operating revenue in FY26. It also earned Rs 4.7 crore from net gains on the sale of investments and other non-operating sources, taking its total income for the year to Rs 143 crore. For the diagnostics firm, employee benefits was the largest cost, accounting for 30% of its overall expenses. The cost rose over 43% to Rs 72.2 crore during the fiscal year. Materials used for testing and diagnostics also increased 40% to Rs 42.9 crore. Claims contract costs were another major expense for the firm, rising to Rs 35.8 crore in FY26, while its spend on marketing and advertising remained largely stable at Rs 34.4 crore. Rent, research and development, IT, legal and professional fees, along with other overheads, added another Rs 55 crore during the year. Overall expenses increased 36% year-on-year to Rs 240.3 crore in FY26 from Rs 175.9 crore in FY25. The Bertelsmann India-backed company’s loss before tax increased 11% year-on-year to Rs 97 crore during the year. The company also booked a deferred tax expense of Rs 49 crore, which took its overall loss to Rs 146 crore. Meanwhile, the company’s EBITDA loss stood at Rs 92.4 crore, with an EBITDA margin of -66.68%. However, the firm claims to have achieved 20% EBITDA profitability in Bengaluru. On a unit level, it spent Rs 1.73 to earn a single rupee of operating revenue in FY26. As at March 2026, Orange Health had total current assets of Rs 55 crore, including Rs 4.5 crore of cash and bank balance. Prior to its $30 million round, Orange Health Labs had raised nearly $50 million in funding. The company raised$12 millionin 2024 in a round led by Amazon Sambhav Venture Fund, followed by a $25 million Series B round in 2022 led by General Catalyst and Bertelsmann India Investments. Orange Health competes with PharmEasy-owned Thyrocare, which reported Rs 829 crore in revenue and Rs 163 crore profit in FY26. Meanwhile, Redcliffe Labs postedRs 419 crorein revenue in
